SLC18A2 Antibody, Biotin conjugated

1. single nucleotide polymorphisms (rs363223, rs363226, rs363251, and rs363341interact with assessed cognitive impairment after severe traumatic brain injury PMID: 26828714
2. This study showed that in Chinese patient population, "GG" of rs363371 in VMAT2 may reduce the risk for ALS. PMID: 28477711
3. We found a novel association between two genetic variants in SLC18A2 and FSH levels in PCOS patients. These findings might indicate a novel regulatory mechanism in follicular development and maturation in PCOS. PMID: 27354380
4. The SLC18A2 gene is hypermethylated and downregulated in prostate cancer (PC). SLC18A2 hypermethylation has promising diagnostic biomarker potential for PC. PMID: 26905753
5. Study found that 2 promoter regions of Vesicular monoamine transporter 2 (hVMAT2) are associated with Parkinson's disease. Study shows that low-activity haplotypes may confer more vulnerability in the presence of a neurotoxin and that hVMAT2 activity could be inhibited by DNA methylation in human dopaminergic neurons. PMID: 27137201
6. No statistically significant differences were found between cases and controls for the allele frequencies in five genes: TH, SLC18A2, DRD1, DRD3 and COMT. Conversely, some alleles of the 12 sNPs from the DRD2 locus and the 5 from the MAOA locus showed significant associations with excessive alcohol consumption. PMID: 26447226
7. describe a second case of infantile-onset movement disorder caused by a different mutation in SLC18A2 compared to PMID:23363473, and partial improvement of symptoms upon treatment with pramipexole; supports identification of causal mutation in index case. PMID: 26497564
8. Two SNPs (rs10082463 & rs363285) of SLC18A2 were nominally associated with cognition. PMID: 23932573
9. The finding of this study provide support for a role of VMAT2 in tardive dyskinesia and add to evidence that VMAT2 may be a potential therapeutic target in the treatment of TD. PMID: 24018103
10. VMAT2 genetic variants contribute to the phenotypes of alcohol dependence. PMID: 23504072
11. Genetic variation in VMAT2 may be linked to alterations in cognitive functioning underlying psychotic disorder, possibly through altered transport of monoamines into synaptic vesicles. PMID: 22532702
12. In an Italian cohort, variability in VMAT2 promoter region appears to confer a reduced risk of developing Parkinson's disease. PMID: 23369548
13. VMAT2 expression dynamically decreased in the neocortex of temporal lobe epilepsy patients when compared with the control subjects. PMID: 23504951
14. Data suggest that pancreatic islets of humans and pigs contain VMAT2 in similar patterns (in beta cells, mast cells, and sympathetic neurons); therefore, the pig (unlike rodents) is potential model for imaging pancreas using radioligands for VMAT2. PMID: 23404442
15. Chromogranin A and vesicular monoamine transporter 2 are localized in protein bodies of human locus coeruleus neurons. PMID: 23573890
16. These results may indicate that VMAT2 expressed in noradrenergic neurons has crucial roles in survival during the first several weeks after birth, and VMAT2 functions in other monoaminergic systems could be required for further extended survival. PMID: 23410751
17. Study evaluated VMAT2 specificity for beta cells in sub-regions of the human pancreas using antibodies targeting VMAT2, insulin and PP by double-label immunofluorescence. PMID: 23221614
18. homology model of VMAT2 shows that molecular hinge points mediate alternating access PMID: 23530208
19. describe a disease encompassing infantile-onset movement disorder and evidence supporting its causation by a mutation in SLC18A2 (which encodes vesicular monoamine transporter 2 [VMAT2]) PMID: 23363473
20. These results support our hypothesis that VMAT-2 and DT-diaphorase are an important defense system against aminochrome formed during dopamine oxidation. PMID: 22483869
21. These results indicate that wild-type DJ-1, but not Parkinson's disease-derived mutant DJ-1, stimulates VMAT2 activity and that C106 is necessary for the stimulating activity of DJ-1 toward VMAT2. PMID: 22554508
22. In an aversive ultrasound-induced defense paradigm, VMAT2(sert-cre) transgenic mice displayed a major increase in escape-like behaviors. PMID: 21814181
23. This preliminary finding indicates a possible structural change in platelet VMAT2 in children with major depressive disorder. PMID: 21484276
24. there is no difference in levels of vesicular monoamine transporter 2 between children with disruptive behavior disorders and healthy volunteers PMID: 21851191
25. Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies. PMID: 21522164
26. A significant reduction of platelet VMAT2 mRNA levels was demonstrated in Parkinson Disease patients versus healthy controls PMID: 20665056
27. Six electroconvulsive therapy sessions are not sufficient for modulation in pVMAT2 expression. Long-term studies are needed to clarify the relationship between full remission and possible alterations in platelet/brain VMAT2 characteristics. PMID: 20544232
28. greater diversity of transcriptional regulations is the driving force for the haplotype selection in SLC18A2 PMID: 20181938
29. Voxel-based analysis demonstrated VMAT2 reductions in the striatum and mid brain of Parkinson disease patients. PMID: 20080893
30. Assessment of the VMAT2 thrombin cleavage site reveals that the Cys-126 in loop 1/2 and Cys-333 in loop 7/8 form a disulfide bond which contributes to efficient monoamine transport. PMID: 12009896
31. Striatal VMAT2 expression was reduced significantly in dementia with Lewy bodies with or without Alzheimer's disease, but was preserved in Alzheimer's disease striatum, permitting postmortem distinction of the two pathologies. PMID: 12112084
32. striatal expression of VMAT2 (as estimated by [(11)C]DTBZ binding) is not coregulated with dopamine synthesis. This is in keeping with a role for VMAT2 in other cellular processes in addition to its importance for the quantal release of monoamines. PMID: 12710012
33. vesicular monoamine transporter (VMAT2) mRNA was not detected in the central part of the placenta but was present in the spiral arteries of placenta bed biopsies PMID: 15135235
34. two single nucleotide polymorphisms were identified that have no detectable effect on most aspects of VMAT2 function, but one may increase sensitivity to the inhibitor tetrabenazine PMID: 15475732
35. SLC18A2 promoter haplotypes defined here create a foundation for transcriptional characterization of individuality and for association study on monoamine-related human diseases PMID: 15829504
36. VMAT2 pharmacodynamic characteristics in a population of medicated schizophrenia patients comparing smokers and nonsmokers. PMID: 16139173
37. Gain-of-function haplotypes in the SLC18A2 promoter are protective for Parkinson disease in women. PMID: 16339215
38. Low expression of VMAT2 in the substantia nigra of Parkinson's disease , the involvement of VMAT2 in Lewy body of the substantia nigra suggests the association of this protein in the neurodegeneration of nigral neurons in Parkinson's disease. PMID: 16386370
39. VMAT 2 antibodies seem more useful for histopathological diagnosis of enterochromaffin-like cell neoplasms than the antibodies to the other CgA regions. PMID: 16408221
40. This review summarizes the possible role of VMAT2 as a therapeutic target and discusses the structure-activity relationships and binding relevance of the VMAT2 ligands reported in the literature. PMID: 17233532
41. lower platelet VMAT2 density occurred in the brain and may serve as an adaptive mechanism geared to decrease dopamine storage PMID: 17344033
42. These results strongly suggest that SVMT gene or certain regions of it may constitute a genetic substrate of susceptibility for both schizophrenia and bipolar disorder. PMID: 17427184
43. data suggest that elements of the 20 S proteasome interact with the VMAT2 promoter to enhance G-protein-coupled receptor-mediated transcription PMID: 17442673
44. Mishandling of dopamine via reduced VMAT2 transgenic expression causes dopamine-mediated toxicity and neurodegeneration in the mouse nigrostriatal dopamine system, replicating key aspects of Parkinson's disease. PMID: 17652604
45. review of the regulation of VMAT2 and the state of the understanding of what measurements of VMAT2 density mean in the context of diabetes PMID: 17665159
46. These data suggest that up-regulated alpha-synuclein expression inhibits the activity of vesicular monoamine transporter-2. PMID: 17985233
47. Variation in SLC18A2 is implicated as risk factor for schizophrenia. PMID: 18045777
48. variation in the VMAT2 gene plays a role in one's openness to spiritual experiences PMID: 18316816
49. Rotenone redistributes VMAT2 via nitration in dopaminergic SH-SY5Y cells. PMID: 18599602
50. Most beta cells expressed VMAT2. VMAT2 expression was not changed by the presence of diabetes. PMID: 18791800

Show More

Hide All

HGNC: 10935

OMIM: 193001

KEGG: hsa:6571

STRING: 9606.ENSP00000298472

UniGene: Hs.596992